Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease

Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease

Background and Aims: In phase 3 induction (ADVANCE and MOTIVATE) and maintenance (FORTIFY) trials, risankizumab was shown to benefit symptom and endoscopic defined outcomes in patients with Crohn’s disease (CD). We examined the effects of risankizumab on the incidence of CD-related hospitalizations...

Full description

Saved in:
Bibliographic Details
Main Authors: Brian G. Feagan, Remo Panaccione, Stefan Schreiber, Edward V. Loftus, Jr., Laurent Peyrin-Biroulet, Takehiro Arai, Wan-Ju Lee, Jenny Griffith, Jasmina Kalabic, Kristina Kligys, Si Xuan, Xiaomei Liao, Marc Ferrante
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Gastro Hep Advances
Subjects:
Crohn’s Disease
Risankizumab
Interleukin-23 Inhibitor
Hospitalizations
Online Access:http://www.sciencedirect.com/science/article/pii/S2772572324001997
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772572324001997

Similar Items